| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Not applicable; this is an isotopically labeled tracer. Unlabeled L-ascorbic acid is an essential cofactor for many enzymes, including prolyl hydroxylase and lysyl hydroxylase (collagen synthesis), dopamine beta-hydroxylase, and the carnitine biosynthesis pathway. It also scavenges reactive oxygen species.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an effect on a drug's pharmacokinetics and metabolic properties, it is a cause for concern [1].
L-Ascorbic acid-13C-2 has the same biological activity as unlabeled ascorbic acid. L-ascorbic acid is a strong reducing agent that neutralizes free radicals, prevents oxidative damage, and regenerates other antioxidants such as vitamin E. It also inhibits Cav3.2 channels with an IC50 of 6.5 microM. |
| ln Vivo |
Unlabeled ascorbic acid is essential for wound healing, immune function, and iron absorption. L-Ascorbic acid-13C-2 is not administered therapeutically but is used as a tracer to study vitamin C pharmacokinetics, tissue distribution, and metabolic turnover in various disease states.
|
| Enzyme Assay |
L-Ascorbic acid-13C-2 is spiked into biological samples (plasma, urine, tissue homogenates) at known concentrations (0.1-10 microg/mL). Samples are stabilized with metaphosphoric acid to prevent oxidation, then analyzed by LC-MS/MS in negative ion mode to quantify endogenous ascorbic acid by isotope dilution.
|
| Cell Assay |
Cells (e.g., hepatocytes, neurons, fibroblasts) are cultured with L-Ascorbic acid-13C-2 (10-200 microM) for 1-24 hours. Cells are harvested in metaphosphoric acid, and the 13C enrichment in ascorbic acid, dehydroascorbic acid, and ascorbate-2-sulfate is measured by LC-MS/MS to study vitamin C uptake and metabolism.
|
| Animal Protocol |
L-Ascorbic acid-13C-2 (10-200 mg/kg) is administered to mice, rats, or guinea pigs (humans and primates) by oral gavage or intraperitoneal injection. Blood (plasma) is collected at 0.5, 1, 2, 4, 6, 12, 24 hours. Tissues (liver, kidney, adrenal, brain) are harvested at terminal time points for LC-MS/MS analysis.
|
| ADME/Pharmacokinetics |
L-ascorbic acid has a plasma half-life of approximately 8-40 days in humans (dose-dependent), but only 1-4 hours in rodents due to endogenous synthesis. Renal reabsorption is saturable; at high doses (>200 mg/day in humans), excess vitamin C is excreted unchanged in urine.
|
| Toxicity/Toxicokinetics |
No toxicity; vitamin C is water-soluble and generally regarded as safe. At very high doses (>2 g/day in humans), it may cause gastrointestinal disturbances (diarrhea, nausea) due to osmotic effects. In patients with glucose-6-phosphate dehydrogenase deficiency, high doses may cause hemolysis.
|
| References | |
| Additional Infomation |
L-Ascorbic acid-13C-2 is for research use only, not FDA-approved as a therapeutic. Unlabeled vitamin C is FDA-approved for the treatment of scurvy and as a dietary supplement. The 13C-labeled version is a valuable internal standard for LC-MS/MS quantification of ascorbic acid in pharmacokinetic, nutritional, and metabolic studies.
|
| Exact Mass |
177.035
|
|---|---|
| CAS # |
1313730-17-4
|
| Related CAS # |
L-Ascorbic acid;50-81-7
|
| PubChem CID |
71309903
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
12
|
| Complexity |
232
|
| Defined Atom Stereocenter Count |
2
|
| SMILES |
C([C@@H]([C@@H]1[13C](=C(C(=O)O1)O)O)O)O
|
| InChi Key |
CIWBSHSKHKDKBQ-VZMNSLOISA-N
|
| InChi Code |
InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1/i3+1
|
| Chemical Name |
(2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-(313C)2H-furan-5-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
